Art

J-GLOBAL ID：201902265960875096   Reference number：19A1821029

Pembrolizumab-induced Ocular Myasthenia Gravis with Anti-titin Antibody and Necrotizing Myopathy

抗titin抗体陽性で壊死性ミオパチーを伴うペンブロリズマブ誘発性眼筋型重症筋無力症

Author (9)： Onda Asako (Department of Neurology, The Jikei University Kashiwa Hospital, Japan) ,  Miyagawa Shinji (Department of Neurology, The Jikei University Kashiwa Hospital, Japan) ,  Takahashi Naoko (Department of Respiratory Medicine, The Jikei University Kashiwa Hospital, Japan) ,  Gochi Mina (Department of Respiratory Medicine, The Jikei University Kashiwa Hospital, Japan) ,  Takagi Masamichi (Department of Respiratory Medicine, The Jikei University Kashiwa Hospital, Japan) ,  Nishino Ichizo (Department of Neuromuscular Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Japan) ,  Suzuki Shigeaki (Department of Neurology, The Keio University School of Medicine, Japan) ,  Oishi Chizuko (Department of Neurology, The Kyorin University Hospital, Japan) ,  Yaguchi Hiroshi (Department of Neurology, The Jikei University Kashiwa Hospital, Japan)
Material： Internal Medicine (Web)  (Intern Med (Web))
Volume： 58  Issue： 11  Page： 1635-1638(J-STAGE)  Publication year： 2019 
JST Material Number： U0033A  ISSN： 1349-7235  Document type： Article
Article type： 原著論文  Country of issue： Japan (JPN)  Language： ENGLISH (EN)

Thesaurus term： human ,...
Semi thesaurus term： 抗titin抗体 ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=19A1821029&from=J-GLOBAL&jstjournalNo=U0033A") }}

Author keywords (5)： pembrolizumab ,  ocular myasthenia gravis ,  anti-titin antibody ,  necrotizing myopathy ,  tubular aggregates

JST classification (4)： Clinical oncology in general  (GE03010Y) ,  Tumors(=neoplasms)of respiratory system  (GI04000G) ,  Musculoskeletal diseases  (GG03000T) ,  Clinical application of antitumor(=antineoplastic)drugs  (GW16020L)

Reference (12)：

• 1. Miyauchi E, Inoue A. Immune checkpoint therapy for non-small-cell lung cancer. Gan To Kagaku Ryoho 43: 666-671, 2016 (in Japanese, Abstract in English).
• 2. Kao JC, Liao B, Markovic SN, et al. Neurological complications associated with anti-programmed death 1 (PD-1) antibodies. JAMA Neurol 74: 1216-1222, 2017.
• 3. Suzuki S, Ishikawa N, Konoeda F, et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 89: 1127-1134, 2017.
• 4. Polat P, Donofrio PD. Myasthenia gravis induced by nivolumab therapy in a patient with non-small-cell lung cancer. Muscle Nerve 54: 507, 2016.
• 5. Nguyen BH, Kuo J, Budiman A, Christie H, Ali S. Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients. Melanoma Res 27: 152-154, 2017.

Terms in the title (4)： 抗体 ,  壊死性ミオパチー ,  ペンブロリズマブ ,  眼筋型重症筋無力症